Wiregraph

Market coverage built from listed-company disclosures. Email [email protected] for any enquiries.

Copyright © 2025-2026 Wiregraph.com | Market data and charting by TradingView.com

GENMAB

GMAB.CODK0010272202NASDAQ CopenhagenDKDKK
Stock price
GENMAB
Loading chart...

Coverage

Latest articles

Genmab's experimental cancer drug shows encouraging results in endometrial cancer trial
8 Jun 2025, 20:28GMAB.CONASDAQ Copenhagen

Filings

Recent filings

FilingDate
Genmab, Report Pursuant to Section 28a of the Danish Securities Trading Act20 Sept 2006
Genmab, Initiates HuMax-EGFr Pivotal Study in Refractory Head and Neck Cancer14 Sept 2006
Genmab, Report Pursuant to Section 28a of the Danish Securities Trading Act8 Sept 2006
InvestorService: Genmab, to Present at Three Investor Conferences in September7 Sept 2006
Genmab, insiders' tradings25 Aug 2006
Genmab, interim report - six months22 Aug 2006
Genmab, Genmab Announces 2006 First Half Year Results22 Aug 2006
Genmab, articles of association dated July 28, 2006
Search

Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.

  • Previous
  • 1
  • 2
  • 3
  • Next
2 Aug 2006
InvestorService: Genmab, Named Finalist for European Biotechnica Award 20062 Aug 2006
Genmab, Capital Increase in Genmab as a Result of Employee Warrant Exercise28 Jul 2006
Genmab, Initiates Ofatumumab (HuMax-CD20) Pivotal Study in NHL10 Jul 2006
Genmab, articles of association dated June 21, 20066 Jul 2006
  • Previous
  • 1
  • More pages
  • 125
  • 126
  • 127
  • More pages
  • 156
  • Next
Company
GENMAB
GMAB.CONASDAQ Copenhagen
Website: Unavailable
Coverage
13
Filings
1,863